BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 11742700)

  • 21. Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel.
    Schuette W; Nagel S; Blankenburg T; Lautenschlaeger C; Hans K; Schmidt EW; Dittrich I; Schweisfurth H; von Weikersthal LF; Raghavachar A; Reissig A; Serke M
    J Clin Oncol; 2005 Nov; 23(33):8389-95. PubMed ID: 16293869
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer.
    Hainsworth JD; Burris HA; Erland JB; Thomas M; Greco FA
    J Clin Oncol; 1998 Jun; 16(6):2164-8. PubMed ID: 9626217
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I trial of weekly docetaxel combined with cisplatin in patients with non-small cell lung cancer.
    Koizumi T; Tsunoda T; Fujimoto K; Nomura H; Hirai K; Koyama S; Okada K; Kubo K
    Lung Cancer; 2001 Oct; 34(1):125-31. PubMed ID: 11557122
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized trial of different docetaxel schedules in non-small cell lung cancer patients who failed previous platinum-based chemotherapy.
    Chen YM; Shih JF; Perng RP; Tsai CM; Whang-Peng J
    Chest; 2006 Apr; 129(4):1031-8. PubMed ID: 16608954
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Weekly chemotherapy with carboplatin, docetaxel and irinotecan in advanced non-small-cell-lung cancer: a phase II study.
    Pectasides D; Visvikis A; Kouloubinis A; Glotsos J; Bountouroglou N; Karvounis N; Ziras N; Athanassiou A
    Eur J Cancer; 2002 Jun; 38(9):1194-200. PubMed ID: 12044505
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Weekly docetaxel as second-line therapy in non-small cell lung cancer: a phase II study.
    Rossi D; Graziano F; Ugolini M; Dennetta D; Alessandroni P; Catalano V; Giordani P; Fedeli SL; Fedeli A; Catalano G
    Tumori; 2004; 90(1):50-3. PubMed ID: 15143972
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A dose escalation study of weekly docetaxel in patients with advanced solid tumors.
    Kouroussis C; Agelaki S; Mavroudis D; Souglakos J; Kakolyris S; Kalbakis K; Vardakis N; Reppa D; Hatzidaki D; Samonis G; Georgoulias V
    Cancer Chemother Pharmacol; 2000; 46(6):488-92. PubMed ID: 11138462
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Docetaxel and granulocyte colony-stimulating factor in patients with advanced non-small-cell lung cancer previously treated with platinum-based chemotherapy: a multicenter phase II trial.
    Alexopoulos K; Kouroussis C; Androulakis N; Papadakis E; Vaslamatzis M; Kakolyris S; Samelis G; Patila E; Vossos A; Samantas E; Georgoulias V
    Cancer Chemother Pharmacol; 1999; 43(3):257-62. PubMed ID: 9923557
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B.
    Akerley W; Herndon JE; Egorin MJ; Lyss AP; Kindler HL; Savarese DM; Sherman CA; Rosen DM; Hollis D; Ratain MJ; Green MR
    Cancer; 2003 May; 97(10):2480-6. PubMed ID: 12733147
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase II study of weekly docetaxel plus capecitabine for patients with advanced nonsmall cell lung carcinoma.
    Han JY; Lee DH; Kim HY; Hong EK; Yoon SM; Chun JH; Lee HG; Lee SY; Shin EH; Lee JS
    Cancer; 2003 Nov; 98(9):1918-24. PubMed ID: 14584075
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I study of docetaxel with concomitant thoracic radiation therapy.
    Mauer AM; Masters GA; Haraf DJ; Hoffman PC; Watson SM; Golomb HM; Vokes EE
    J Clin Oncol; 1998 Jan; 16(1):159-64. PubMed ID: 9440738
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I trial of outpatient weekly docetaxel, carboplatin and concurrent thoracic radiation therapy for stage III unresectable non-small-cell lung cancer: a Vanderbilt cancer center affiliate network (VCCAN) trial.
    Choy H; DeVore RF; Hande KR; Porter LL; Rosenblatt PA; Slovis B; Laporte K; Shyr Y; Johnson DH
    Lung Cancer; 2001 Dec; 34(3):441-9. PubMed ID: 11714542
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase I trial of weekly docetaxel and cisplatinum combined to concurrent hyperfractionated radiotherapy for non-small cell lung cancer and squamous cell carcinoma of head and neck.
    Varveris H; Mazonakis M; Vlachaki M; Kachris S; Lyraraki E; Zoras O; Maris T; Froudarakis M; Velegrakis J; Perysinakis C; Damilakis J; Samonis G
    Oncol Rep; 2003; 10(1):185-95. PubMed ID: 12469168
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II trial of docetaxel in previously untreated advanced non-small-cell lung cancer: a Japanese cooperative study.
    Kunitoh H; Watanabe K; Onoshi T; Furuse K; Niitani H; Taguchi T
    J Clin Oncol; 1996 May; 14(5):1649-55. PubMed ID: 8622084
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian group for the study of digestive tract cancer.
    Cascinu S; Graziano F; Barni S; Labianca R; Comella G; Casaretti R; Frontini L; Catalano V; Baldelli AM; Catalano G
    Br J Cancer; 2001 Feb; 84(4):470-4. PubMed ID: 11207039
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low-dose weekly paclitaxel as second-line treatment for advanced non-small cell lung cancer: a phase II study.
    Juan O; Albert A; Ordoño F; Casany R; Carañana V; Campos JM; Alberola V
    Jpn J Clin Oncol; 2002 Nov; 32(11):449-54. PubMed ID: 12499416
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sequential versus concurrent paclitaxel and carboplatin for the treatment of advanced non-small cell lung cancer in elderly patients and patients with poor performance status: results of two Phase II, multicenter trials.
    Marsland TA; Garfield DH; Khan MM; Look RM; Boehm KA; Asmar L
    Lung Cancer; 2005 Jan; 47(1):111-20. PubMed ID: 15603861
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Docetaxel and irinotecan, alone and in combination, in the treatment of non-small cell lung cancer.
    Adjei AA; Argiris A; Murren JR
    Semin Oncol; 1999 Oct; 26(5 Suppl 16):32-40; discussion 41-2. PubMed ID: 10585007
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Concurrent conventionally factionated radiotherapy and weekly docetaxel in the treatment of stage IIIb non-small-cell lung carcinoma.
    Koukourakis MI; Bahlitzanakis N; Froudarakis M; Giatromanolaki A; Georgoulias V; Koumiotaki S; Christodoulou M; Kyrias G; Skarlatos J; Kostantelos J; Beroukas K
    Br J Cancer; 1999 Aug; 80(11):1792-6. PubMed ID: 10468298
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Weekly docetaxel as a single agent and in combination with gemcitabine in elderly and poor performance status patients with advanced non--small cell lung cancer.
    Hainsworth JD; Burris HA; Greco FA
    Semin Oncol; 2001 Jun; 28(3 Suppl 9):21-5. PubMed ID: 11441411
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.